Fedley Healthcare: India's Trusted Ofloxacin 200mg + Nitazoxanide 500mg Tablet

DCGI Approved WHO-GMP
Tablets & Capsules

OFLORIV-NZ

Product Composition

Ofloxacin 200mg + Nitazoxanide 500mg Tablet

Packing
10*10
Release Type
ALU/ALU
DCGI Approved
WHO-GMP Certified
ALU/ALU
Pan India Delivery
Get Franchise QuoteWhatsApp Us
ISO 9001:2015
1000+ Products
29+ States
Share:

Uses of OFLORIV-NZ

Ofloxacin 200mg + Nitazoxanide 500mg Tablet is prescribed for various conditions related to inflammation, pain, and joint disorders.

Quality-Driven Manufacturing Behind OFLORIV-NZ

1000+
DCGI Approved Products
12+
Years of Experience
2000+
Franchise Partners
29+
States Covered

PCD Pharma Franchise for Ofloxacin 200mg + Nitazoxanide 500mg Tablet — Available Across India

Fedley Healthcare provides exclusive monopoly-based PCD franchise rights for OFLORIV-NZ in all major states and union territories across India.

PunjabHaryanaRajasthanUttar PradeshMadhya PradeshGujaratMaharashtraKarnatakaTamil NaduKeralaAndhra PradeshTelanganaWest BengalBiharJharkhandOdishaChhattisgarhAssamMeghalayaTripuraManipurNagalandMizoramArunachal PradeshSikkimUttarakhandHimachal PradeshGoaJammu & KashmirDelhi NCRChandigarhPuducherry

Exclusive monopoly rights available — contact us to check availability in your state & district.

Why Fedley Healthcare vs Other Manufacturers?

See how we compare with typical pharma manufacturers in India.

Factor
Fedley Healthcare
Others
WHO-GMP Certification
Certified
Often Not
DCGI Approved Products
1000+
Limited
Monopoly Rights
Exclusive Territory
Shared
Marketing Support
Visual Aids, LBLs, Gifts
Minimal / Paid
Product Quality
SR Technology
Standard
Delivery
Pan India, On-Time
Delayed
MOQ (Min Order)
Flexible & Low
High Minimum
Profit Margins
Attractive (High ROI)
Thin Margins
Ethical Promotion
100% Ethical
Questionable
Franchise Support
Dedicated Manager
No Post-Sale Support
WHO-GMP Certification
Fedley
Certified
Others
Often Not
DCGI Approved Products
Fedley
1000+
Others
Limited
Monopoly Rights
Fedley
Exclusive Territory
Others
Shared
Marketing Support
Fedley
Visual Aids, LBLs, Gifts
Others
Minimal / Paid
Product Quality
Fedley
SR Technology
Others
Standard
Delivery
Fedley
Pan India, On-Time
Others
Delayed
MOQ (Min Order)
Fedley
Flexible & Low
Others
High Minimum
Profit Margins
Fedley
Attractive (High ROI)
Others
Thin Margins
Ethical Promotion
Fedley
100% Ethical
Others
Questionable
Franchise Support
Fedley
Dedicated Manager
Others
No Post-Sale Support

Start Your Pharma Business with OFLORIV-NZ — Get Exclusive Franchise Rights in Your State Today

Join 2000+ successful franchise partners across India. Low investment, high returns, complete marketing support.

Get Franchise Quote Now

Get Franchise Quote for OFLORIV-NZ

Interested in Ofloxacin 200mg + Nitazoxanide 500mg Tablet for your pharma franchise business? Fill the form and our team will get back to you with pricing, MOQ, and exclusive territory details.

  • Exclusive Monopoly Rights in Your Territory
  • Attractive Profit Margins & Low Investment
  • Timely Product Delivery Across India
  • Free Promotional Support (Visual Aids, LBLs, Gifts)

Send Enquiry

Fill in your details and we'll contact you shortly.

Product: OFLORIV-NZ | Ofloxacin 200mg + Nitazoxanide 500mg Tablet

Or call us: +91-9855986633 | +91-9317692852

Customer Reviews

4.7based on 87 ratings

OFLORIV-NZ has shown excellent results in my clinical practice. The Ofloxacin 200mg + Nitazoxanide 500mg Tablet formulation is well-balanced and patients report good tolerance with consistent therapeutic outcomes.

VS

Vikram Singh

Verified Purchase

12 Jun 2025

Excellent bioavailability with OFLORIV-NZ. The Ofloxacin 200mg + Nitazoxanide 500mg Tablet formulation is well-researched. Good product quality backed by proper DCGI documentation.

DN

Dr. Neha Joshi

Verified Purchase

14 Nov 2025

Highly recommend OFLORIV-NZ — the Ofloxacin 200mg + Nitazoxanide 500mg Tablet formulation is potent and well-manufactured. Timely delivery and proper documentation from Fedley Healthcare.

DR

Dr. Rekha Mishra

Verified Purchase

22 Jan 2026